Breath Analysis Innovation

Breath Sensing and Analysis of Biological
Indicators for Disease Diagnosis

Biological indicators provide a link between exhaled breath and disease diagnosis.

TERTIARY INDICATORS

Tertiary indicators such as insulin resistance are byproducts of progressed disease and represent the current standard of diagnosis.

SECONDARY INDICATORS

Secondary indicators such as volatile organic compounds (VOCs) are byproducts of a disturbance in biological function early in disease progression.

PRIMARY INDICATORS

Primary indicators such as mis-folded proteins originate from within the cells themselves at the earliest stages of disease development.

The presence of primary and secondary indictors in exhaled breath provides the basis for early, non-invasive disease diagnosis and monitoring.

TRACE-E™, a medical device built around Trace Sensing’s proprietary Thermodynamic Sensor platform, is capable of detecting target indicators with unprecedented sensitivity.

This non-invasive medical device analyzes the concentration of target indicators in exhaled breath in real-time, providing results in seconds with greater sensitivity than standard blood and urine tests. 

Enabled by highly specific catalyst tuning, each “fingerprint” is unique ensuring the accurate diagnosis of several diseases.

The system then generates “fingerprints” for exhaled breath resulting in the identification and differentiation of specific proteins, VOCs and combinations thereof.

This innovation holds the promise of improving health-span by providing vital diagnostic information earlier than ever possible, empowering better decisions for living longer, healthier lives. 

The Trace Sensing Advantage

SINGLE MOLECULE DETECTION

TRACE-E™ utilizes the first sensor capable of single molecule detection in the vapor phase enabling identification of small particles at near-zero concentration levels in vivo, including genetic material, proteins, and other previously undetectable small molecules. 

REAL-TIME AND NON-INVASIVE

TRACE-E™ is capable of real-time analysis of exhaled breath without the need for sample collection or preparation. Breath is delivered directly into the device non-invasively and exactly how it appears during exhalation to ensure biological relevancy.

FOUNDATIONAL INDICATOR DATABASE

Trace Sensing has compiled a comprehensive library of primary and secondary indicators and their associated diseases which ensures the highest levels of accuracy and effectiveness. This approach provides a foundational chemical and biological understanding of disease and acts as a reference point with which to compare real-world data.

TRACE-E will be less expensive, non-invasive, and faster than the current standard of care.

Current standards are much less sensitive and have a slower response rate.

EARLY USE CASES INCLUDE

  • Early-stage disease detection and diagnosis.

  • Disease progression and therapeutic response monitoring.

  • Precision medicine applications including cell and gene therapy.

  • Drug discovery and development.

Focused on conditions with available treatments that lack a diagnostic standard or have a standard that is ineffective or cost prohibitive.

THERAPUTIC FOCUS AREAS

  • Neurodegenerative and movement disorders.

  • Cardiometabolic diseases.

  • Certain cancers.

Non-Invasive Cardiometabolic Monitoring via Breath Analysis

Non-invasive glucose monitoring via TRACE-E showed a 92.65% and 96.69% correlation to blood glucose in a male and female patient respectively.

Each catalyst employed in the sensor array is capable of displaying three qualitative responses (positive, negative, no response) resulting in an exhaled breath “fingerprint.” Each “fingerprint” is selective to the set of catalysts and the corresponding molecules.

Primary indicators (folded/misfolded proteins) & secondary indicators (VOCs) intervention at the earliest stages of pathogenesis.

The sensitivity, selectivity, and flexibility to generate an almost endless combination of “fingerprints” in real-time provides the basis for a rapid, non-invasive disease diagnosis platform via exhaled breath analysis.